MYGN · Myriad Genetics Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted free cash flow non-GAAP | -$10.9M | second quarter 2026 | — |
|
|
|||
| Adjusted operating cash outflow non-GAAP | -$7.7M | second quarter 2026 | — |
|
|
|||
| Adjusted operating expenses non-GAAP | $150.5M | second quarter 2026 | — |
|
|
|||
| Cancer Care Continuum product volumes | 95K | Three months ended June 30, 2026 | — |
|
|
|||
| Mental Health product volumes | 140K | Three months ended June 30, 2026 | — |
|
|
|||
| Prenatal Health product volumes | 144K | Three months ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | -$4.5M | first quarter 2026 | — |
|
|
|||
| Hereditary cancer test volumes | 82K | Three months ended December 31, 2025 | — |
| Mental Health test volumes | 138K | Three months ended December 31, 2025 | — |
| Prenatal test volumes | 150K | Three months ended December 31, 2025 | — |
| Total test volumes | 1.54M | Twelve Months Ended December 31, 2025 | — |
| Tumor profiling test volumes | 12K | Three months ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MYGN
this stock
Myriad Genetics Inc
|
$289.82M | -50.7% | -7.1% | — | 8.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MYGN | -7.1% | -51.0% | -30.8% | +5.9% | -50.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -7.5% | -55.4% | -44.6% | +2.0% | -64.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.